drugset / Trial / NCT06679465

Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response

NCT06679465

Phase 4 Not yet recruiting 10 enrolled University of Saskatchewan
RandomizedCrossoverTriple-blindTreatment

Summary

Evaluate single dose (2 x 2.5mcg/puff; total dose 5mcg) effect of tiotropium administered 30 minutes prior to allergen challenge on allergen-induced EAR assessed as the maximal % fall in FEV1 after allergen inhalation compared to that of single dose (two puffs) matched placebo administered 30 minutes prior to allergen challenge.

Timeline

Start
2025-01-01
Primary completion
2027-01
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 5 ug

Indications